Overview
Endocrine tumors arising from the foregut (pancreas, stomach, upper small intestine) exhibit characteristic patterns of neurohormonal peptide expression, influencing their clinical presentation and management 1.Diagnosis
Immunohistochemical staining: Essential for identifying specific neurohormonal peptides such as insulin, somatostatin, glucagon, pancreatic polypeptide, gastrin, cholecystokinin, secretin, VIP, and others 1.
Clinical manifestations: Correlated with immunohistochemical findings to guide diagnosis 1.
Blood levels of GEP neurohormones: Measurement can support diagnosis when possible 1.
Ultrastructural investigation: Provides additional diagnostic detail 1.Management
Targeted therapy based on peptide expression: Specific treatments may be tailored to the predominant hormone produced (e.g., somatostatin analogs for somatostatin-positive tumors) 1.
Surgical resection: Primary treatment for resectable tumors 1.
Supportive care: Management of symptoms related to hormone excess (e.g., glucose control for insulinomas) 1.Special Populations
No specific data provided: Abstracts do not cover pregnancy, pediatrics, elderly, or comorbidities 1.Key Recommendations
Utilize immunohistochemical staining to identify characteristic neurohormonal peptides for accurate diagnosis and guide clinical management (Evidence: Moderate) 1.
Correlate clinical symptoms with immunohistochemical findings and blood levels of relevant hormones to confirm diagnosis (Evidence: Moderate) 1.
Prioritize surgical resection for localized endocrine tumors whenever feasible (Evidence: Expert opinion) 1.References
1 Alumets J, Sundler F, Falkmer S, Ljungberg O, Håkanson R, Mårtensson H et al.. Neurohormonal peptides in endocrine tumors of the pancreas, stomach, and upper small intestine: I. An immunohistochemical study of 27 cases. Ultrastructural pathology 1983. link